Page last updated: 2024-11-11

batimastat

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

batimastat: structure given in first source; a synthetic matrix metalloproteinase inhibitor [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

batimastat : A secondary carboxamide resulting from the formal condensation of the carboxy group of (2S,3R)-5-methyl-3-{[(2S)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]carbamoyl}-2-[(thiophen-2-ylsulfanyl)methyl]hexanoic acid with the amino group of hydroxylamine. It a broad-spectrum matrix metalloprotease inhibitor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5362422
CHEMBL ID279786
CHEBI ID195398
SCHEMBL ID4332
MeSH IDM0216168

Synonyms (68)

Synonym
bb-94
isv-120
isv-615
D03061
batimastat (usan/inn)
(2s,3r)-5-methyl-3-(((alphas)-alpha-(methylcarbamoyl)phenethyl)carbamoyl)-2-((2-thienylthio)methyl)hexanohydroxamic acid
butanediamide, n(sup 4)-hydroxy-n(sup 1)-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2r-(1(s*),2r*,3s*))-
bb 94
4-(n-hydroxyamino)-2r-isobutyl-2s-(2-thienylthiomethyl)succinyl-l-phenylalanine-n-methylamide
butanediamide, n4-hydroxy-n1-(2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl)-2-(2-methylpropyl)-3-((2-thienylthio)methyl)-, (2r-(1(s*),2r*,3s*))-
batimastat
130370-60-4
bb94, bb-94
(2r)-n-[(1s)-1-benzyl-2-(methylamino)-2-oxo-ethyl]-2-[(1s)-2-(hydroxyamino)-2-oxo-1-(2-thienylsulfanylmethyl)ethyl]-4-methyl-pentanamide
2J83
1RM8
DB03880
bb94
CHEMBL279786 ,
(2s,3r)-n-hydroxy-n'-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-3-(2-methylpropyl)-2-(thiophen-2-ylsulfanylmethyl)butanediamide
bdbm50063918
(2r,3s)-n*4*-hydroxy-2-isobutyl-n*1*-((s)-1-methylcarbamoyl-2-phenyl-ethyl)-3-(thiophen-2-ylsulfanylmethyl)-succinamide
4-methyl-2-[1-methyl-2-(thiophen-2-ylsulfanyl)-ethyl]-pentanoic acid (1-methylcarbamoyl-2-phenyl-ethyl)-amide
n*4*-hydroxy-2-isobutyl-n*1*-(1-methylcarbamoyl-2-phenyl-ethyl)-3-(thiophen-2-ylsulfanylmethyl)-succinamide
CHEBI:195398
batimastatum
(2r,3s)-n(4)-hydroxy-n(1)-[(2s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]-2-(2-methylpropyl)-3-[(thiophen-2-ylsulfanyl)methyl]butanediamide
batimastat [usan:inn:ban]
unii-bk349f52c9
bk349f52c9 ,
(2r,3s)-n-hydroxy-n'-[(1s)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)-3-[(thiophen-2-ylsulfanyl)methyl]butanediamide
batimastat (bb-94)
NCGC00346877-01
batimastat [inn]
batimastat [mart.]
batimastat [mi]
batimastat [usan]
S7155
BRD-K82818427-001-01-4
gtpl5145
(2s,3r)-n1-hydroxy-3-isobutyl-n4-((s)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl)-2-((thiophen-2-ylthio)methyl)succinamide
HY-13564
CS-1655
smr002530309
MLS006011226
MLS006010631
SCHEMBL4332
AKOS024457355
(2r,3s)-n4-hydroxy-n1-[(1s)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]butanediamide
AC-33099
DTXSID20156497
mfcd00866533
batimastat (mmp inhibitor)
J-005800
butanediamide, n4-hydroxy-n1-[(1s)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-3-[(2-thienylthio)methyl]-, (2r,3s)-
batimastat, >=98% (hplc)
batimastat(bb-94)
(2r,3s)-n~1~-[(1s)-1-benzyl-2-(methylamino)-2-oxoethyl]-n~4~-hydroxy-2-(2-methylpropyl)-3-[(thiophen-2-ylsulfanyl)methyl]butanediamide
batimastat; bb94
batimastat - cas 130370-60-4
EX-A1671
AS-75198
(2r,3s)-n'-hydroxy-n-[(1s)-1-(methylcarbamoyl)-2-phenylethyl]-2-(2-methylpropyl)-3-[(thiophen-2-ylsulfanyl)methyl]butanediamide
Q15303190
BRD-K82818427-001-04-8
A12985
CCG-269520
BB162029

Research Excerpts

Overview

Batimastat (BB-94) is a broad-spectrum MMP inhibitor that causes resolution of ascites and/or tumor growth delay in animal models of breast, ovarian, and colorectal cancer. It has been shown to inhibit tumor growth and metastasis in mice.

ExcerptReferenceRelevance
"Batimastat, or BB-94, is a synthetic broad-spectrum MMP inhibitor not previously examined in periodontal research."( Influence of the matrix metalloproteinase inhibitor batimastat (BB-94) on periodontal bone destruction in Sprague-Dawley rats.
Björnsson, MJ; Havemose-Poulsen, A; Holmstrup, P; Stoltze, K, 2004
)
1.3
"Batimastat is a highly effective metalloproteinase enzyme blocker, with the potential to reduce the degradation of extracellular matrix and to inhibit the migration of smooth muscle cells, with the consequent capacity to control coronary restenosis."( [Batimastat-eluting stent implantation for the treatment of coronary artery disease: results of the Brazilian pilot study].
Araujo, CM; Cristóvão, SA; Mangione, JA; Mauro, MF; Oliveira Neto, JB; Rando, GA; Salman, AA; Sanchez, IS, 2005
)
1.96
"Batimastat (BB-94) is a broad-spectrum MMP inhibitor that causes resolution of ascites and/or tumor growth delay in animal models of breast, ovarian, and colorectal cancer."( Phase I study of intrapleural batimastat (BB-94), a matrix metalloproteinase inhibitor, in the treatment of malignant pleural effusions.
Braybrooke, JP; Brown, P; Gleeson, F; Harris, AL; Long, L; Macaulay, VM; Mason, CS; O'Byrne, KJ; Saunders, MP; Talbot, DC, 1999
)
1.31
"Batimastat (BB-94) is a synthetic MMP inhibitor that has been shown to inhibit tumor growth and metastasis in mice."( The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells.
Chambers, AF; Groom, AC; MacDonald, IC; Morris, VL; Schmidt, EE; Varghese, HJ; Wylie, S, 1999
)
1.29

Effects

ExcerptReferenceRelevance
"Batimastat has been found to decrease cell proliferation evaluated by a number of PCNA-positive stained cell nuclei."( Inhibition of estrogen-induced pituitary tumor growth and angiogenesis in Fischer 344 rats by the matrix metalloproteinase inhibitor batimastat.
Godlewski, A; Meleń-Mucha, G; Mucha, SA; Stepień, H, 2007
)
1.26

Actions

Batimastat plays a role in the protection of the lung injury of CBP by reducing the concentration and activity of MMP-9. It also reduces the degradation of the cell membrane and pulmonary neutrophil infiltration.

ExcerptReferenceRelevance
"Batimastat plays a role in the protection of the lung injury of CBP by reducing the concentration and activity of MMP-9, the degradation of the cell membrane and pulmonary neutrophil infiltration and reduction of pulmonary edema."( [Protective role of MMP-9 inhibitor batimastat in acute lung injury after cardiopulmonary bypass].
Feng, JB; Ge, SL; Gong, WH; Han, PH; Zhang, CX; Zhang, L; Zhang, SQ; Zhou, DC, 2010
)
2.08
"Batimastat also did not inhibit early survival of cells."( The matrix metalloproteinase inhibitor batimastat inhibits angiogenesis in liver metastases of B16F1 melanoma cells.
Chambers, AF; Groom, AC; MacDonald, IC; Morris, VL; Schmidt, EE; Varghese, HJ; Wylie, S, 1999
)
1.29

Treatment

Batimastat treatment also caused liver-specific overexpression of MMPs-2, -9, and mRNA up-regulation of angiogenesis factors and caspase-1. Treatment with batimstat in our ascites model produced no increase in survival or significant suppression of ascites formation.

ExcerptReferenceRelevance
"Batimastat treatment did not affect cellular levels of MMP or TIMP-2 mRNAs."( Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice.
Bone, EA; Fife, R; Goulet, R; Qulali, M; Sledge, GW, 1995
)
1.27
"Batimastat treatment also caused liver-specific overexpression of MMPs-2, -9, and mRNA up-regulation of angiogenesis factors and caspase-1, even in tumor-free animals."( Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis.
Arlt, M; Gänsbacher, B; Harbeck, N; Kopitz, C; Krüger, A; Magdolen, V; Schmitt, M; Soeltl, R; Sopov, I, 2001
)
1.28
"Batimastat treatment was effective in reducing MMP-2 and MMP-9 activity as well as the tissue inhibitor of metalloproteinase-1 (TIMP-1) level in BAL."( Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
Boichot, E; Caulet-Maugendre, S; Corbel, M; Germain, N; Lagente, V; Molet, S, 2001
)
1.25
"Treatment with batimastat in our ascites model produced no increase in survival or significant suppression of ascites formation."( The matrix metalloproteinase inhibitor batimastat (BB-94) retards human breast cancer solid tumor growth but not ascites formation in nude mice.
Bone, EA; Dickson, RB; Johnson, MD; Low, JA, 1996
)
0.9

Toxicity

ExcerptReferenceRelevance
"The ability of two peptidomimetic hydroxamate metalloproteinase inhibitors, Batimastat and Marimastat, to abrogate toxic and proteinase activities of the venom of Echis ocellatus from Cameroon and Ghana was assessed."( Peptidomimetic hydroxamate metalloproteinase inhibitors abrogate local and systemic toxicity induced by Echis ocellatus (saw-scaled) snake venom.
Arias, AS; Gutiérrez, JM; Rucavado, A, 2017
)
0.68

Bioavailability

ExcerptReferenceRelevance
" The drug was well absorbed via the intraperitoneal route and associated with few side-effects."( Phase I/II trial of batimastat, a matrix metalloproteinase inhibitor, in patients with malignant ascites.
Parsons, SL; Steele, RJ; Watson, SA, 1997
)
0.62
" The hydroxamate peptidomimetic inhibitor batimastat and its orally bioavailable analogue marimastat, which bind covalently to the zinc atom at the MMP-active site, were the first MMP inhibitors to be studied in detail."( Development of matrix metalloproteinase inhibitors in cancer therapy.
Eckhardt, SG; Hidalgo, M, 2001
)
0.57
"Ro-28-2653, a selective and orally bioavailable MMPI with inhibitory activity against MMPs expressed by tumor and/or stromal cells, is a potent antitumor and antiangiogenic agent."( Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor.
Devy, L; Foidart, JM; Frankenne, F; Grams, F; Krell, HW; Maquoi, E; Noël, A; Olivier, F; Sounni, NE, 2004
)
0.32
" CHR-2797 is orally bioavailable and currently undergoing phase II clinical investigation in the treatment of myeloid leukemia."( CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells.
Ayscough, A; Bawden, LJ; Bone, EA; Box, G; Callaghan, J; Chandler, S; Clark, VL; Drummond, AH; Eccles, SA; Farmer, H; Flores, N; Kirwin-Jones, P; Krige, D; Laber, D; Legris, V; Miles, LE; Needham, LA; Odedra, R; Owen, J; Patel, T; Stone, E; Wood, LM; Wood, S; Wright, A, 2008
)
0.35
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" Thus IFN-gamma is cytotoxic to ovarian epithelial cells in vivo and intensive locoregional dosing over short periods is effective."( Interferon gamma induces cell cycle arrest and apoptosis in a model of ovarian cancer: enhancement of effect by batimastat.
Balkwill, FR; Burke, F; East, N; Patel, K; Upton, C, 1997
)
0.51
" Batimastat (30 mg/kg) or vehicle alone was administered by intraperitoneal injection 24 h and 1 h before saline or bleomycin instillation, and then daily at the same dosage until the end of the study."( Inhibition of bleomycin-induced pulmonary fibrosis in mice by the matrix metalloproteinase inhibitor batimastat.
Boichot, E; Caulet-Maugendre, S; Corbel, M; Germain, N; Lagente, V; Molet, S, 2001
)
1.44
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
matrix metalloproteinase inhibitornull
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
angiogenesis inhibitorAn agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (6)

ClassDescription
L-phenylalanine derivativeA proteinogenic amino acid derivative resulting from reaction of L-phenylalanine at the amino group or the carboxy group, or from the replacement of any hydrogen of L-phenylalanine by a heteroatom.
thiophenesCompounds containing at least one thiophene ring.
organic sulfideCompounds having the structure RSR (R =/= H). Such compounds were once called thioethers.
triamide
hydroxamic acidA compound, RkE(=O)lNHOH, derived from an oxoacid RkE(=O)l(OH) (l =/= 0) by replacing -OH with -NHOH, and derivatives thereof. Specific examples of hydroxamic acids are preferably named as N-hydroxy amides.
secondary carboxamideA carboxamide resulting from the formal condensation of a carboxylic acid with a primary amine; formula RC(=O)NHR(1).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (19)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency6.74120.01237.983543.2770AID1645841
EWS/FLI fusion proteinHomo sapiens (human)Potency16.12490.001310.157742.8575AID1259252; AID1259253
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)IC50 (µMol)0.02500.00042.08059.0000AID242037
5-hydroxytryptamine receptor 3BHomo sapiens (human)IC50 (µMol)0.02500.00041.95059.0000AID242037
Interstitial collagenaseHomo sapiens (human)IC50 (µMol)0.31580.00020.850210.0000AID104923; AID108730; AID108731; AID108753; AID1853405; AID73283; AID73284
Low affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)IC50 (µMol)0.10000.04000.31001.0000AID44531; AID44532
72 kDa type IV collagenaseHomo sapiens (human)IC50 (µMol)0.30290.00001.284810.0000AID104925; AID107155; AID109579; AID109580; AID1853406; AID242036
Stromelysin-1Homo sapiens (human)IC50 (µMol)1.12050.00001.148410.0000AID104927; AID107357; AID107358; AID107498; AID1853407
MatrilysinHomo sapiens (human)IC50 (µMol)3.50120.00142.085910.0000AID104928; AID1853408
Matrix metalloproteinase-9Homo sapiens (human)IC50 (µMol)0.00660.00000.705310.0000AID108005; AID108007; AID108021; AID242037
Neutrophil collagenaseHomo sapiens (human)IC50 (µMol)0.70000.00000.927210.0000AID1853409
Metabotropic glutamate receptor 5Rattus norvegicus (Norway rat)IC50 (µMol)1.20000.00000.52627.9700AID683161
Collagenase 3Homo sapiens (human)IC50 (µMol)0.00500.00000.767510.0000AID109252
5-hydroxytryptamine receptor 3AHomo sapiens (human)IC50 (µMol)0.02500.00011.07899.0000AID242037
Matrix metalloproteinase-14Homo sapiens (human)IC50 (µMol)0.57150.00030.718210.0000AID109549; AID109551; AID1853410; AID220527; AID242053
Disintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)IC50 (µMol)0.01490.00021.014010.0000AID215278
Snake venom metalloproteinase BaP1Bothrops asper (terciopelo)IC50 (µMol)1.20001.20001.20001.2000AID683161
5-hydroxytryptamine receptor 3DHomo sapiens (human)IC50 (µMol)0.02500.00042.08059.0000AID242037
5-hydroxytryptamine receptor 3CHomo sapiens (human)IC50 (µMol)0.02500.00042.08059.0000AID242037
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (153)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
proteolysisInterstitial collagenaseHomo sapiens (human)
protein metabolic processInterstitial collagenaseHomo sapiens (human)
extracellular matrix disassemblyInterstitial collagenaseHomo sapiens (human)
collagen catabolic processInterstitial collagenaseHomo sapiens (human)
positive regulation of protein-containing complex assemblyInterstitial collagenaseHomo sapiens (human)
cellular response to UV-AInterstitial collagenaseHomo sapiens (human)
extracellular matrix organizationInterstitial collagenaseHomo sapiens (human)
B cell antigen processing and presentationLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
positive regulation of humoral immune response mediated by circulating immunoglobulinLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
Fc-epsilon receptor signaling pathwayLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
macrophage activationLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
positive regulation of nitric-oxide synthase activityLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
positive regulation of killing of cells of another organismLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic processLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
Fc receptor-mediated immune complex endocytosisLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
biological process involved in interspecies interaction between organismsLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
immune responseLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
angiogenesis72 kDa type IV collagenaseHomo sapiens (human)
ovarian follicle development72 kDa type IV collagenaseHomo sapiens (human)
ovulation from ovarian follicle72 kDa type IV collagenaseHomo sapiens (human)
luteinization72 kDa type IV collagenaseHomo sapiens (human)
blood vessel maturation72 kDa type IV collagenaseHomo sapiens (human)
intramembranous ossification72 kDa type IV collagenaseHomo sapiens (human)
proteolysis72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of cell adhesion72 kDa type IV collagenaseHomo sapiens (human)
heart development72 kDa type IV collagenaseHomo sapiens (human)
embryo implantation72 kDa type IV collagenaseHomo sapiens (human)
parturition72 kDa type IV collagenaseHomo sapiens (human)
response to xenobiotic stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to mechanical stimulus72 kDa type IV collagenaseHomo sapiens (human)
peripheral nervous system axon regeneration72 kDa type IV collagenaseHomo sapiens (human)
response to activity72 kDa type IV collagenaseHomo sapiens (human)
protein metabolic process72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix disassembly72 kDa type IV collagenaseHomo sapiens (human)
protein catabolic process72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of cell migration72 kDa type IV collagenaseHomo sapiens (human)
collagen catabolic process72 kDa type IV collagenaseHomo sapiens (human)
response to retinoic acid72 kDa type IV collagenaseHomo sapiens (human)
cellular response to reactive oxygen species72 kDa type IV collagenaseHomo sapiens (human)
response to nicotine72 kDa type IV collagenaseHomo sapiens (human)
endodermal cell differentiation72 kDa type IV collagenaseHomo sapiens (human)
response to hydrogen peroxide72 kDa type IV collagenaseHomo sapiens (human)
response to estrogen72 kDa type IV collagenaseHomo sapiens (human)
negative regulation of vasoconstriction72 kDa type IV collagenaseHomo sapiens (human)
ephrin receptor signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
macrophage chemotaxis72 kDa type IV collagenaseHomo sapiens (human)
response to electrical stimulus72 kDa type IV collagenaseHomo sapiens (human)
response to hyperoxia72 kDa type IV collagenaseHomo sapiens (human)
face morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
bone trabecula formation72 kDa type IV collagenaseHomo sapiens (human)
prostate gland epithelium morphogenesis72 kDa type IV collagenaseHomo sapiens (human)
cellular response to amino acid stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to interleukin-172 kDa type IV collagenaseHomo sapiens (human)
cellular response to estradiol stimulus72 kDa type IV collagenaseHomo sapiens (human)
cellular response to UV-A72 kDa type IV collagenaseHomo sapiens (human)
cellular response to fluid shear stress72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of oxidative stress-induced neuron intrinsic apoptotic signaling pathway72 kDa type IV collagenaseHomo sapiens (human)
response to amyloid-beta72 kDa type IV collagenaseHomo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferation72 kDa type IV collagenaseHomo sapiens (human)
extracellular matrix organization72 kDa type IV collagenaseHomo sapiens (human)
response to hypoxia72 kDa type IV collagenaseHomo sapiens (human)
tissue remodeling72 kDa type IV collagenaseHomo sapiens (human)
proteolysisStromelysin-1Homo sapiens (human)
extracellular matrix disassemblyStromelysin-1Homo sapiens (human)
protein catabolic processStromelysin-1Homo sapiens (human)
regulation of cell migrationStromelysin-1Homo sapiens (human)
collagen catabolic processStromelysin-1Homo sapiens (human)
positive regulation of protein-containing complex assemblyStromelysin-1Homo sapiens (human)
cellular response to reactive oxygen speciesStromelysin-1Homo sapiens (human)
innate immune responseStromelysin-1Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionStromelysin-1Homo sapiens (human)
cellular response to lipopolysaccharideStromelysin-1Homo sapiens (human)
cellular response to amino acid stimulusStromelysin-1Homo sapiens (human)
cellular response to UV-AStromelysin-1Homo sapiens (human)
cellular response to nitric oxideStromelysin-1Homo sapiens (human)
regulation of neuroinflammatory responseStromelysin-1Homo sapiens (human)
response to amyloid-betaStromelysin-1Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processStromelysin-1Homo sapiens (human)
extracellular matrix organizationStromelysin-1Homo sapiens (human)
membrane protein ectodomain proteolysisMatrilysinHomo sapiens (human)
membrane protein intracellular domain proteolysisMatrilysinHomo sapiens (human)
antibacterial peptide secretionMatrilysinHomo sapiens (human)
antibacterial peptide biosynthetic processMatrilysinHomo sapiens (human)
proteolysisMatrilysinHomo sapiens (human)
response to xenobiotic stimulusMatrilysinHomo sapiens (human)
extracellular matrix disassemblyMatrilysinHomo sapiens (human)
positive regulation of cell migrationMatrilysinHomo sapiens (human)
collagen catabolic processMatrilysinHomo sapiens (human)
regulation of cell population proliferationMatrilysinHomo sapiens (human)
defense response to Gram-negative bacteriumMatrilysinHomo sapiens (human)
defense response to Gram-positive bacteriumMatrilysinHomo sapiens (human)
extracellular matrix organizationMatrilysinHomo sapiens (human)
skeletal system developmentMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of protein phosphorylationMatrix metalloproteinase-9Homo sapiens (human)
proteolysisMatrix metalloproteinase-9Homo sapiens (human)
apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
embryo implantationMatrix metalloproteinase-9Homo sapiens (human)
cell migrationMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-9Homo sapiens (human)
macrophage differentiationMatrix metalloproteinase-9Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-9Homo sapiens (human)
cellular response to reactive oxygen speciesMatrix metalloproteinase-9Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of apoptotic processMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of DNA bindingMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
ephrin receptor signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of keratinocyte migrationMatrix metalloproteinase-9Homo sapiens (human)
cellular response to lipopolysaccharideMatrix metalloproteinase-9Homo sapiens (human)
cellular response to cadmium ionMatrix metalloproteinase-9Homo sapiens (human)
cellular response to UV-AMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaMatrix metalloproteinase-9Homo sapiens (human)
regulation of neuroinflammatory responseMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of receptor bindingMatrix metalloproteinase-9Homo sapiens (human)
response to amyloid-betaMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of vascular associated smooth muscle cell proliferationMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of epithelial cell differentiation involved in kidney developmentMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cation channel activityMatrix metalloproteinase-9Homo sapiens (human)
negative regulation of cysteine-type endopeptidase activity involved in apoptotic signaling pathwayMatrix metalloproteinase-9Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-9Homo sapiens (human)
positive regulation of microglial cell activationNeutrophil collagenaseHomo sapiens (human)
proteolysisNeutrophil collagenaseHomo sapiens (human)
extracellular matrix disassemblyNeutrophil collagenaseHomo sapiens (human)
collagen catabolic processNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor productionNeutrophil collagenaseHomo sapiens (human)
endodermal cell differentiationNeutrophil collagenaseHomo sapiens (human)
cellular response to lipopolysaccharideNeutrophil collagenaseHomo sapiens (human)
positive regulation of neuroinflammatory responseNeutrophil collagenaseHomo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayNeutrophil collagenaseHomo sapiens (human)
extracellular matrix organizationNeutrophil collagenaseHomo sapiens (human)
endochondral ossificationCollagenase 3Homo sapiens (human)
growth plate cartilage developmentCollagenase 3Homo sapiens (human)
proteolysisCollagenase 3Homo sapiens (human)
extracellular matrix disassemblyCollagenase 3Homo sapiens (human)
bone mineralizationCollagenase 3Homo sapiens (human)
collagen catabolic processCollagenase 3Homo sapiens (human)
bone morphogenesisCollagenase 3Homo sapiens (human)
response to amyloid-betaCollagenase 3Homo sapiens (human)
extracellular matrix organizationCollagenase 3Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
angiogenesisMatrix metalloproteinase-14Homo sapiens (human)
ovarian follicle developmentMatrix metalloproteinase-14Homo sapiens (human)
response to hypoxiaMatrix metalloproteinase-14Homo sapiens (human)
endothelial cell proliferationMatrix metalloproteinase-14Homo sapiens (human)
endochondral ossificationMatrix metalloproteinase-14Homo sapiens (human)
proteolysisMatrix metalloproteinase-14Homo sapiens (human)
response to oxidative stressMatrix metalloproteinase-14Homo sapiens (human)
male gonad developmentMatrix metalloproteinase-14Homo sapiens (human)
response to mechanical stimulusMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of myotube differentiationMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of protein processingMatrix metalloproteinase-14Homo sapiens (human)
response to organic cyclic compoundMatrix metalloproteinase-14Homo sapiens (human)
protein processingMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix disassemblyMatrix metalloproteinase-14Homo sapiens (human)
protein catabolic processMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell growthMatrix metalloproteinase-14Homo sapiens (human)
lung developmentMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of cell migrationMatrix metalloproteinase-14Homo sapiens (human)
collagen catabolic processMatrix metalloproteinase-14Homo sapiens (human)
zymogen activationMatrix metalloproteinase-14Homo sapiens (human)
endodermal cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
chondrocyte proliferationMatrix metalloproteinase-14Homo sapiens (human)
astrocyte cell migrationMatrix metalloproteinase-14Homo sapiens (human)
response to estrogenMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of B cell differentiationMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of Notch signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
embryonic cranial skeleton morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
branching morphogenesis of an epithelial tubeMatrix metalloproteinase-14Homo sapiens (human)
tissue remodelingMatrix metalloproteinase-14Homo sapiens (human)
cell motilityMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of focal adhesion assemblyMatrix metalloproteinase-14Homo sapiens (human)
head developmentMatrix metalloproteinase-14Homo sapiens (human)
craniofacial suture morphogenesisMatrix metalloproteinase-14Homo sapiens (human)
negative regulation of GDF15-GFRAL signaling pathwayMatrix metalloproteinase-14Homo sapiens (human)
regulation of protein localization to plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of macrophage migrationMatrix metalloproteinase-14Homo sapiens (human)
response to odorantMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrix organizationMatrix metalloproteinase-14Homo sapiens (human)
skeletal system developmentMatrix metalloproteinase-14Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to hypoxiaDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
neutrophil mediated immunityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
germinal center formationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of leukocyte chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane protein ectodomain proteolysisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch receptor processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell population proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to xenobiotic stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of T cell chemotaxisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein processingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
signal releaseDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
B cell differentiationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell growthDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
response to lipopolysaccharideDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of chemokine productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor productionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
regulation of mast cell apoptotic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
T cell differentiation in thymusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell adhesion mediated by integrinDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
wound healing, spreading of epidermal cellsDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of blood vessel endothelial cell migrationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor-activated receptor activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
spleen developmentDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell motilityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
defense response to Gram-positive bacteriumDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cellular response to high density lipoprotein particle stimulusDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
commissural neuron axon guidanceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
negative regulation of cold-induced thermogenesisDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of tumor necrosis factor-mediated signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
positive regulation of vascular endothelial cell proliferationDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch signaling pathwayDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (30)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
endopeptidase activityInterstitial collagenaseHomo sapiens (human)
metalloendopeptidase activityInterstitial collagenaseHomo sapiens (human)
serine-type endopeptidase activityInterstitial collagenaseHomo sapiens (human)
peptidase activityInterstitial collagenaseHomo sapiens (human)
zinc ion bindingInterstitial collagenaseHomo sapiens (human)
protease bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
integrin bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
protein bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
low-affinity IgE receptor activityLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
IgE bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
metal ion bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
carbohydrate bindingLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
fibronectin binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
metalloendopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
serine-type endopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
protein binding72 kDa type IV collagenaseHomo sapiens (human)
metallopeptidase activity72 kDa type IV collagenaseHomo sapiens (human)
zinc ion binding72 kDa type IV collagenaseHomo sapiens (human)
endopeptidase activityStromelysin-1Homo sapiens (human)
metalloendopeptidase activityStromelysin-1Homo sapiens (human)
serine-type endopeptidase activityStromelysin-1Homo sapiens (human)
protein bindingStromelysin-1Homo sapiens (human)
peptidase activityStromelysin-1Homo sapiens (human)
metallopeptidase activityStromelysin-1Homo sapiens (human)
zinc ion bindingStromelysin-1Homo sapiens (human)
endopeptidase activityMatrilysinHomo sapiens (human)
metalloendopeptidase activityMatrilysinHomo sapiens (human)
serine-type endopeptidase activityMatrilysinHomo sapiens (human)
protein bindingMatrilysinHomo sapiens (human)
metallopeptidase activityMatrilysinHomo sapiens (human)
zinc ion bindingMatrilysinHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
protein bindingMatrix metalloproteinase-9Homo sapiens (human)
collagen bindingMatrix metalloproteinase-9Homo sapiens (human)
peptidase activityMatrix metalloproteinase-9Homo sapiens (human)
metallopeptidase activityMatrix metalloproteinase-9Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-9Homo sapiens (human)
identical protein bindingMatrix metalloproteinase-9Homo sapiens (human)
endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
metalloendopeptidase activityNeutrophil collagenaseHomo sapiens (human)
serine-type endopeptidase activityNeutrophil collagenaseHomo sapiens (human)
peptidase activityNeutrophil collagenaseHomo sapiens (human)
zinc ion bindingNeutrophil collagenaseHomo sapiens (human)
tumor necrosis factor bindingNeutrophil collagenaseHomo sapiens (human)
endopeptidase activityCollagenase 3Homo sapiens (human)
metalloendopeptidase activityCollagenase 3Homo sapiens (human)
serine-type endopeptidase activityCollagenase 3Homo sapiens (human)
calcium ion bindingCollagenase 3Homo sapiens (human)
collagen bindingCollagenase 3Homo sapiens (human)
zinc ion bindingCollagenase 3Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
metalloendopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
serine-type endopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
integrin bindingMatrix metalloproteinase-14Homo sapiens (human)
protein bindingMatrix metalloproteinase-14Homo sapiens (human)
zinc ion bindingMatrix metalloproteinase-14Homo sapiens (human)
metalloaminopeptidase activityMatrix metalloproteinase-14Homo sapiens (human)
endopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Notch bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
interleukin-6 receptor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
integrin bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
peptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metallopeptidase activityDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
SH3 domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytokine bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
PDZ domain bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
tumor necrosis factor bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metal ion bindingDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
metalloendopeptidase activity involved in amyloid precursor protein catabolic processDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (36)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
extracellular regionInterstitial collagenaseHomo sapiens (human)
extracellular matrixInterstitial collagenaseHomo sapiens (human)
extracellular spaceInterstitial collagenaseHomo sapiens (human)
plasma membraneLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
extracellular exosomeLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
external side of plasma membraneLow affinity immunoglobulin epsilon Fc receptorHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular region72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
nucleus72 kDa type IV collagenaseHomo sapiens (human)
mitochondrion72 kDa type IV collagenaseHomo sapiens (human)
plasma membrane72 kDa type IV collagenaseHomo sapiens (human)
sarcomere72 kDa type IV collagenaseHomo sapiens (human)
collagen-containing extracellular matrix72 kDa type IV collagenaseHomo sapiens (human)
extracellular space72 kDa type IV collagenaseHomo sapiens (human)
extracellular regionStromelysin-1Homo sapiens (human)
nucleusStromelysin-1Homo sapiens (human)
mitochondrionStromelysin-1Homo sapiens (human)
cytosolStromelysin-1Homo sapiens (human)
extracellular matrixStromelysin-1Homo sapiens (human)
extracellular spaceStromelysin-1Homo sapiens (human)
extracellular regionMatrilysinHomo sapiens (human)
extracellular matrixMatrilysinHomo sapiens (human)
extracellular exosomeMatrilysinHomo sapiens (human)
extracellular spaceMatrilysinHomo sapiens (human)
extracellular regionMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
collagen-containing extracellular matrixMatrix metalloproteinase-9Homo sapiens (human)
extracellular exosomeMatrix metalloproteinase-9Homo sapiens (human)
tertiary granule lumenMatrix metalloproteinase-9Homo sapiens (human)
ficolin-1-rich granule lumenMatrix metalloproteinase-9Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-9Homo sapiens (human)
extracellular regionNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
specific granule lumenNeutrophil collagenaseHomo sapiens (human)
collagen-containing extracellular matrixNeutrophil collagenaseHomo sapiens (human)
tertiary granule lumenNeutrophil collagenaseHomo sapiens (human)
extracellular spaceNeutrophil collagenaseHomo sapiens (human)
extracellular regionCollagenase 3Homo sapiens (human)
extracellular matrixCollagenase 3Homo sapiens (human)
extracellular spaceCollagenase 3Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
cytoplasmMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
nucleusMatrix metalloproteinase-14Homo sapiens (human)
Golgi lumenMatrix metalloproteinase-14Homo sapiens (human)
cytosolMatrix metalloproteinase-14Homo sapiens (human)
plasma membraneMatrix metalloproteinase-14Homo sapiens (human)
focal adhesionMatrix metalloproteinase-14Homo sapiens (human)
extracellular matrixMatrix metalloproteinase-14Homo sapiens (human)
cytoplasmic vesicleMatrix metalloproteinase-14Homo sapiens (human)
melanosomeMatrix metalloproteinase-14Homo sapiens (human)
macropinosomeMatrix metalloproteinase-14Homo sapiens (human)
intermediate filament cytoskeletonMatrix metalloproteinase-14Homo sapiens (human)
extracellular spaceMatrix metalloproteinase-14Homo sapiens (human)
cell-cell junctionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
focal adhesionDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
ruffle membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
Golgi membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytoplasmDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
endoplasmic reticulum lumenDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cytosolDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
cell surfaceDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
actin cytoskeletonDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
apical plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
membrane raftDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membraneDisintegrin and metalloproteinase domain-containing protein 17Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (73)

Assay IDTitleYearJournalArticle
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID108731Activity against Matrix metalloprotease-1 (MMP-1).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID104928In vitro inhibitory activity against human recombinant matrix metalloprotease 71998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID242036Inhibition of human matrix metalloprotease-2 expressed in Sf9 insect cells2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID107358Activity against Matrix metalloprotease-3 (MMP-3).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1853405Inhibition of human MMP-12021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID108007Activity against Matrix metalloprotease-9 (MMP-9).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID220527Activity against deletion mutant of MT1-MMP lacking the transmembrane domain (deltaMT1)1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID1853413Inhibition of human HDAC8 by fluorometric method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID683161Inhibition of snake venom BaP1 using Abz-Ala-Gly-Leu-Ala-Nba as substrate incubated for 30 mins prior to substrate addition by fluorescence spectrophotometry2012ACS medicinal chemistry letters, Jul-12, Volume: 3, Issue:7
Identification of new snake venom metalloproteinase inhibitors using compound screening and rational Peptide design.
AID108730Inhibition of Matrix metalloprotease-12001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID108005Inhibition of Matrix metalloprotease-92001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID1853410Inhibition of human MMP-142021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID242053Inhibition of human matrix metalloprotease-14 expressed in Escherichia coli2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID1853409Inhibition of human MMP-82021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID109579Ability to inhibit the matrix metalloprotease-2 by method of Knight et al using the fluorogenic peptide substrate.2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID107155Inhibition of human matrix metalloprotease-2 (MMP-2)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID215278Inhibition of Tumor necrosis factor alpha converting enzyme (TACE)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID109580Activity against Matrix metalloprotease-2 (MMP-2).1998Journal of medicinal chemistry, Apr-09, Volume: 41, Issue:8
Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
AID242289Inhibitory concentration against adipocyte-derived leucine aminopeptidase; ND = Not determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID109551Inhibition of Matrix metalloprotease-142003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID109252Inhibition of Matrix metalloprotease-132003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID109549Inhibition of Matrix metalloprotease-142001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID161637Inhibitory activity against Procollagen C-terminal proteinase (PCP); Not tested2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID108753Inhibition of human Matrix metalloprotease-1 (MMP-1)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID107357Ability to inhibit the matrix metalloprotease-3 by method of Knight et al using the fluorogenic peptide substrate.2001Bioorganic & medicinal chemistry letters, Feb-26, Volume: 11, Issue:4
Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
AID44531Tested for inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells ( a human B-cell line)1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing.
AID44532Inhibition against CD23 (IgE receptor) proteolysis in membranes derived from RPM18866 cells1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Selective inhibition of low affinity IgE receptor (CD23) processing.
AID104923In vitro inhibitory activity against matrix metalloprotease 1 isolated from the culture medium of human skin fibroblasts induced with PMA1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1853412Inhibition of human HDAC3 by fluorometric method2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID104925In vitro inhibitory activity against matrix metalloprotease 2 isolated from human HT1080 fibrosarcoma cells induced with TNF1998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1853407Inhibition of human MMP-32021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID107498Inhibition of human matrix metalloprotease-3 (MMP-3)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID1853406Inhibition of human MMP-22021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID108021Inhibition of human matrix metalloprotease-9 (MMP-9)2003Journal of medicinal chemistry, Jul-31, Volume: 46, Issue:16
A potent, selective inhibitor of matrix metalloproteinase-3 for the topical treatment of chronic dermal ulcers.
AID1853411Inhibition of human TACE by fluorescence based assay2021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID1853408Inhibition of human MMP-72021RSC medicinal chemistry, Oct-20, Volume: 12, Issue:10
AID242037Inhibition of human matrix metalloprotease-9 expressed in Sf9 insect cells2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID73283Inhibitory activity towards human recombinant fibroblast collagenase1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing.
AID241731Inhibitory concentration against aminopeptidase N; ND = Not determined2005Bioorganic & medicinal chemistry letters, Jan-03, Volume: 15, Issue:1
N-hydroxy-2-(naphthalene-2-ylsulfanyl)-acetamide, a novel hydroxamic acid-based inhibitor of aminopeptidase N and its anti-angiogenic activity.
AID73284Inhibitory activity towards human recombinant fibroblast collagenase1998Bioorganic & medicinal chemistry letters, Jan-06, Volume: 8, Issue:1
Selective inhibition of low affinity IgE receptor (CD23) processing.
AID104927In vitro inhibitory activity against human recombinant matrix metalloprotease 31998Bioorganic & medicinal chemistry letters, Nov-17, Volume: 8, Issue:22
Aryl ketones as novel replacements for the C-terminal amide bond of succinyl hydroxamate MMP inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (325)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's100 (30.77)18.2507
2000's162 (49.85)29.6817
2010's50 (15.38)24.3611
2020's13 (4.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 32.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index32.50 (24.57)
Research Supply Index5.87 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index45.55 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (32.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (1.73%)5.53%
Reviews19 (5.48%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other322 (92.80%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]